GT Biopharma initiated with a Buy at Roth MKM

Roth MKM initiated coverage of GT Biopharma (GTBP) with a Buy rating and $11 price target Clinical-stage GT is developing unique precision therapeutic agents using camelid-derived nanobodies, the analyst tells investors in a research note. The firm says the drugs are designed to treat various cancers and autoimmune disorders, and the versatility of these nanobodies enables them to be engineered for optimal therapeutic effects, offering potential benefits such as reduced side effects and more convenient routes of delivery.